SUNPHARMA's weekly performance was relatively stable, with a modest return of 0.15% amidst high volatility of 19.5%. The stock outperformed its peers, DRREDDY and DIVISLAB, which saw significant losses, but underperformed HINDUNILVR, which had a slightly higher return. The Sharpe Ratio of 0.03 indicates that the stock's return was not substantial enough to justify its risk, and the Max Drawdown of -1.48% suggests that it was a relatively risky investment this week.

[Volatility: 19.5%]